PMEL
Melanocyte protein PMEL
As of the edition of 20 October 2026, PMEL (melanocyte protein PMEL, UniProt P40967) has 2 drugs tested at it and 2 companies on the list, 0 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P40967
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 20
- Disease areas
- Cancer; Eye; Skin and connective tissue
- Registered trials of its drugs
- 20
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Tebentafusp | Marketed | Phase 3 | Ends 2034 |
| DYP688 | Active | Phase 2 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 1 |
| Engaged | 1 |
| Total on the list | 2 |
| Company | Route |
|---|---|
| Immunocore | Route B |
The other 1 company at PMEL
In the product2 companies in all; 1 is not named here, and no score is.
See the 2 companies at PMEL, ranked, with the facts behind eachRequest access. Nothing is shown until you do.